StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Vor Biopharma (VOR) Reiterated at Buy by Stifel on Telitacicept’s Potential for gMG
September 28, 2026 7:40 AM
Stifel analyst Stephen Willey reiterated a Buy rating and $40.00 price target on Vor Biopharma, Inc. (NASDAQ: VOR).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
